Bares R, Galonska P, Dempke W, Handt S, Büll U, Osieka R
Department of Nuclear Medicine, Technical University of Aachen, Germany.
Horm Metab Res Suppl. 1993;27:56-8.
Somatostatin receptor scintigraphy with 111In-labeled octreotide was performed in 22 patients with suspected or known malignant lymphoma. The majority of extra-abdominal lesions (21/24 = 87.5%) were correctly localized, however, only one of nine intraabdominal lymphomas could be detected. No significant correlation was found between scintigraphic results and histological type of lymphoma. Metabolic imaging by positron-emission tomography with 18F-labeled deoxyglucose yielded a higher rate of detection of lymphoma manifestations (92% vs 64%) and better tumor contrast. Further prospective studies are needed to establish the clinical relevance of somatostatin receptor scintigraphy in malignant lymphoma.
对22例疑似或确诊为恶性淋巴瘤的患者进行了用111铟标记奥曲肽的生长抑素受体闪烁扫描。大多数腹外病变（21/24 = 87.5%）被正确定位，然而，九例腹内淋巴瘤中仅一例可被检测到。闪烁扫描结果与淋巴瘤组织学类型之间未发现显著相关性。用18F标记脱氧葡萄糖的正电子发射断层扫描进行的代谢成像对淋巴瘤表现的检测率更高（92%对64%）且肿瘤对比度更好。需要进一步的前瞻性研究来确定生长抑素受体闪烁扫描在恶性淋巴瘤中的临床相关性。
